Blood cancers, Myeloma
Open
Phase 1/2
This study is looking at a drug called SAR445514 for myeloma and light chain amyloidosis.
It is open to people with myeloma and light chain amyloidosis that has come back after treatment or got worse during treatment.
Please note the study is only open to people with myeloma at the moment. We will update this summary when the study is open to people with light chain amyloidosis.
Recruitment start: 1 November 2023
Recruitment end: 11 September 2026
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Emma Searle
Sanofi
Last reviewed: 12 August 2024
CRUK internal database number: 19781